Last reviewed · How we verify
Relapsed or refractory follicular lymphoma
Approved treatments
- Pf-07985631 · Pfizer
- Pf-07985631 · Pfizer
- Pf-07985631 · Pfizer
- Pf-07985631 · Pfizer
- Pf-07985631 · Pfizer
- Pf-07985631 · Pfizer
- Pf-07985631 · Pfizer
- LUNSUMIO · GENENTECH INC
- Lunsumio · Roche
Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsed or refractory follicular lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Relapsed or refractory follicular lymphoma treatment landscape brief
- Relapsed or refractory follicular lymphoma treatment updates RSS
Frequently asked questions about Relapsed or refractory follicular lymphoma
What drugs treat Relapsed or refractory follicular lymphoma?
Tracked treatments include Pf-07985631, LUNSUMIO, Lunsumio.
What is the treatment for Relapsed or refractory follicular lymphoma?
Standard treatment for Relapsed or refractory follicular lymphoma includes Pf-07985631, LUNSUMIO, Lunsumio. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsed or refractory follicular lymphoma patent cliff · Relapsed or refractory follicular lymphoma CI report
- Treatment: Pf-07985631 · Pfizer
- Treatment: Pf-07985631 · Pfizer
- Treatment: Pf-07985631 · Pfizer
- Treatment: Pf-07985631 · Pfizer
- Treatment: Pf-07985631 · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing